ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Investment analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “hold” rating and a $22.00 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential […]